425 related articles for article (PubMed ID: 16517716)
1. Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis.
Zhu B; Guleria I; Khosroshahi A; Chitnis T; Imitola J; Azuma M; Yagita H; Sayegh MH; Khoury SJ
J Immunol; 2006 Mar; 176(6):3480-9. PubMed ID: 16517716
[TBL] [Abstract][Full Text] [Related]
2. PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE.
Schreiner B; Bailey SL; Shin T; Chen L; Miller SD
Eur J Immunol; 2008 Oct; 38(10):2706-17. PubMed ID: 18825752
[TBL] [Abstract][Full Text] [Related]
3. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
[TBL] [Abstract][Full Text] [Related]
4. Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand.
Hirata S; Senju S; Matsuyoshi H; Fukuma D; Uemura Y; Nishimura Y
J Immunol; 2005 Feb; 174(4):1888-97. PubMed ID: 15699115
[TBL] [Abstract][Full Text] [Related]
5. PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis.
Carter LL; Leach MW; Azoitei ML; Cui J; Pelker JW; Jussif J; Benoit S; Ireland G; Luxenberg D; Askew GR; Milarski KL; Groves C; Brown T; Carito BA; Percival K; Carreno BM; Collins M; Marusic S
J Neuroimmunol; 2007 Jan; 182(1-2):124-34. PubMed ID: 17182110
[TBL] [Abstract][Full Text] [Related]
6. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles.
Menke J; Lucas JA; Zeller GC; Keir ME; Huang XR; Tsuboi N; Mayadas TN; Lan HY; Sharpe AH; Kelley VR
J Immunol; 2007 Dec; 179(11):7466-77. PubMed ID: 18025191
[TBL] [Abstract][Full Text] [Related]
7. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis.
Salama AD; Chitnis T; Imitola J; Ansari MJ; Akiba H; Tushima F; Azuma M; Yagita H; Sayegh MH; Khoury SJ
J Exp Med; 2003 Jul; 198(1):71-8. PubMed ID: 12847138
[TBL] [Abstract][Full Text] [Related]
8. The PD-1/PD-L pathway is up-regulated during IL-12-induced suppression of EAE mediated by IFN-gamma.
Cheng X; Zhao Z; Ventura E; Gran B; Shindler KS; Rostami A
J Neuroimmunol; 2007 Apr; 185(1-2):75-86. PubMed ID: 17320975
[TBL] [Abstract][Full Text] [Related]
9. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation.
Kanai T; Totsuka T; Uraushihara K; Makita S; Nakamura T; Koganei K; Fukushima T; Akiba H; Yagita H; Okumura K; Machida U; Iwai H; Azuma M; Chen L; Watanabe M
J Immunol; 2003 Oct; 171(8):4156-63. PubMed ID: 14530338
[TBL] [Abstract][Full Text] [Related]
10. Fine-tuned expression of programmed death 1 ligands in mature dendritic cells stimulated by CD40 ligand is critical for the induction of an efficient tumor specific immune response.
Gu T; Zhu YB; Chen C; Li M; Chen YJ; Yu GH; Ge Y; Zhou SY; Zhou H; Huang Y; Qiu YH; Zhang XG
Cell Mol Immunol; 2008 Feb; 5(1):33-9. PubMed ID: 18318992
[TBL] [Abstract][Full Text] [Related]
11. Expression of programmed death 1 ligands by murine T cells and APC.
Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions.
Akbari O; Stock P; Singh AK; Lombardi V; Lee WL; Freeman GJ; Sharpe AH; Umetsu DT; Dekruyff RH
Mucosal Immunol; 2010 Jan; 3(1):81-91. PubMed ID: 19741598
[TBL] [Abstract][Full Text] [Related]
13. Mice deficient for CCR6 fail to control chronic experimental autoimmune encephalomyelitis.
Elhofy A; Depaolo RW; Lira SA; Lukacs NW; Karpus WJ
J Neuroimmunol; 2009 Aug; 213(1-2):91-9. PubMed ID: 19535153
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell upregulation of programmed death ligand-1 via DNA demethylation inhibits experimental autoimmune encephalomyelitis.
Chang CB; Lee SP; Chen WM; Wang CM; Song YC; Chan MW; Wu SF
J Autoimmun; 2020 Feb; 107():102362. PubMed ID: 31787479
[TBL] [Abstract][Full Text] [Related]
15. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine.
He YF; Zhang GM; Wang XH; Zhang H; Yuan Y; Li D; Feng ZH
J Immunol; 2004 Oct; 173(8):4919-28. PubMed ID: 15470033
[TBL] [Abstract][Full Text] [Related]
16. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production.
Yamazaki T; Akiba H; Koyanagi A; Azuma M; Yagita H; Okumura K
J Immunol; 2005 Aug; 175(3):1586-92. PubMed ID: 16034097
[TBL] [Abstract][Full Text] [Related]
17. Novel immunomodulatory properties of berbamine through selective down-regulation of STAT4 and action of IFN-gamma in experimental autoimmune encephalomyelitis.
Ren Y; Lu L; Guo TB; Qiu J; Yang Y; Liu A; Zhang JZ
J Immunol; 2008 Jul; 181(2):1491-8. PubMed ID: 18606704
[TBL] [Abstract][Full Text] [Related]
18. Cutting Edge: Programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens.
Martin-Orozco N; Wang YH; Yagita H; Dong C
J Immunol; 2006 Dec; 177(12):8291-5. PubMed ID: 17142723
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.
Ishida M; Iwai Y; Tanaka Y; Okazaki T; Freeman GJ; Minato N; Honjo T
Immunol Lett; 2002 Oct; 84(1):57-62. PubMed ID: 12161284
[TBL] [Abstract][Full Text] [Related]
20. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis.
Vanderlugt CL; Neville KL; Nikcevich KM; Eagar TN; Bluestone JA; Miller SD
J Immunol; 2000 Jan; 164(2):670-8. PubMed ID: 10623809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
